Convetra
horse1

Our goal is to develop products for veterinary use that are focused on large unmet areas of need, and that are based on data-driven evaluation and rigorous clinical trials. Convetra utilizes the power of a radioactive medical nuclide, tin-117m, as a platform technology using different formulations for various indications in a number of animal species. Convetra is a subsidiary of Serene, LLC, which has a rich history of scientific rigor, utilization of proven experts in the fields of nuclear medicine and veterinary medicine, and an experienced management team.

Synovetin OATM, our initial product, has completed enrollment of a multicenter pivotal clinical trial in client owned dogs with elbow osteoarthritis at the University of Missouri College of Veterinary Medicine, Louisiana State University School of Veterinary Medicine, and Gulf Coast Veterinary Services in Houston, Texas. There are greater than 80 million dogs in the United States, and fourteen million of these have some degree of activity limiting osteoarthritis in at least one joint. The most common medical treatment for this condition is systemic oral non-steroidal anti-inflammatory medications which may not adequately ameliorate the pain and inflammation in specific joints of active dogs, and which may also result in unwanted side effects. In our clinical trial Synovetin OATM is administered by veterinarians as a single intra-articular injection into the elbow of dogs with naturally occurring elbow osteoarthritis, and these patients are tested and monitored throughout the following 12 months. We anticipate introducing Synovetin OATM in 2018 to treat canine elbow osteoarthritis, with additional joint indications for dogs to follow thereafter.

dog-running7Synovetin OATM is ordered by prescribing veterinarians as needed and is supplied in a single use vial with the specific dose required for the size of the dog and joint being treated. The product is designed as a single intra-articular injection to reduce pain and inflammation (synovitis) of joints afflicted with osteoarthritis. The therapeutic effect may last for many months to over a year in properly selected dogs. There have been no adverse effects noted in subjects that have been properly injected, or any unforeseen safety issues identified for the owners or medical personnel.

Radiation exposure to the dog is limited to the injected joint only, and there is negligible exposure to the rest of the animal. Owners and health care providers’ exposure is minimal and safe, and can be easily handled. Radioactive material licenses for receipt and use of the product are required, and easy-to-use training modules that are state-specific will be made available before the date of commercialization.

Future projects in canine medicine include additional research about other joints affected by osteoarthritis, oncology therapies and stents. We have additional plans for the use of tin-117m in equine for the treatment of osteoarthritis, laminitis, and specific cancers, as well as a plans to treat feline osteoarthritis.

Clinical Studies

Companion Animal Clinical Trials

active-cat-otherCanine osteoarthritis

  • An investigational safety trial of Synovetin OATM has been completed on five normal hounds. Data collection included histopathology, autoradiography, blood laboratory, joint fluid cytology, imaging, excretion radiation, and radiation field determination. These data demonstrated safety to subject dogs and caregivers, and joint retention >99.0%.
  • An investigational trial of Synovetin OATM in grade 1-2 elbow osteoarthritis has completed enrollment at the University of Missouri College of Veterinary Medicine, Louisiana State University School of Veterinary Medicine, and Gulf Coast Veterinary Specialists in Houston, Texas. This trial will determine the safety and efficacy of tin-117m colloid in client-owned dogs with naturally occurring osteoarthritis of the elbow joint and includes collection and evaluation of blood, joint fluid cytology, imaging (MRI/CT/PET), excretion radiation, radiation field determination, owner assessment, investigator physical assessment, force plate, and video gait analysis in the following 12 months.
  • An investigational trial of Synovetin OATM in grade 3 elbow osteoarthritis has completed enrollment at the Louisiana State University School of Veterinary Medicine, and Gulf Coast Veterinary Specialists in Houston, Texas. This trial will determine the safety and efficacy of tin-117m colloid in client-owned dogs with naturally occurring osteoarthritis of the elbow joint and includes collection and evaluation of blood, joint fluid cytology, imaging (MRI/CT), excretion radiation, radiation field determination, owner assessment, investigator physical assessment, force plate, and video gait analysis in the following 12 months.
  • An investigational trial of Synovetin OATM repeat injection in grade 1-3 elbow osteoarthritis has completed enrollment at the Louisiana State University School of Veterinary Medicine and the University of Missouri College of Veterinary Medicine. This trial will determine the safety and efficacy of repeat injections of tin-117m colloid in client-owned dogs with naturally occurring osteoarthritis of the elbow joint and includes collection and evaluation of blood, joint fluid cytology, imaging (MRI/CT/PET), excretion radiation, radiation field determination, owner assessment, investigator physical assessment, force plate, and video gait analysis in the following 6 months.

Equine osteoarthritis

  • A proof of concept trial is being developed to treat naturally occurring osteoarthritis in horses. This trial will be conducted at a leading University of Veterinary Medicine in the United States.

Preclinical Trials

Tin-117m colloid has been used in multiple non-GLP and GLP trials including a Lewis rat meniscal tear model of osteoarthritis. The non-GLP trial demonstrated safety, efficacy, and dosing information, and validated joint retention of >99%. A larger GLP trial has been completed, which validated the results of the non-GLP trial.

Publications

Companion Animals

Preclinical

  • “[Sn-117m]-DOTA-annexin V Treatment of Carotid and Coronary Plaque in Apo-e Mice”, H. Strauss, et. al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2016 Meeting, une 11-15, San Diego, CA
  • “Validation of the Use of Homogeneous Sn-117m Colloid Radiosynoviorthesis in a GLP Osteoarthritis Rat Model”, C. Doerr, et. al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2016 Meeting, June 11-15, San Diego, CA
  • “Homogeneous Sn-117m Colloid Radiosynovectomy Results in Rat Models of Joint Disease”, C.A. Doerr, et. al., SNMMI, Baltimore, June 2015, Poster